• Loading stock data…

ITM Announces First Patient Treated in Second Phase III Trial, COMPOSE, with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors

[#item_full_content]

Print Friendly, PDF & Email
Spread the word